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Available online 23 October 2012The anti-inflammatory potential of Boswellia serrata gum resin extracts has been demonstrated in
vitro and in animal studies as well as in pilot clinical trials. However, pharmacokinetic studies
have evidenced low systemic absorption of boswellic acids (BAs), especially of KBA and AKBA, in
rodents and humans. This observation has provided a rationale to improve the formulation of
Boswellia extract. We present here the results of a murine comparative bioavailability study
of Casperome™, a soy lecithin formulation of standardized B. serrata gum resin extract (BE),
and its corresponding non-formulated extract. The concentration of the six major BAs
[11-keto-β-boswellic acid (KBA), acetyl-11-keto-β-boswellic acid (AKBA), β-boswellic acid
(βBA), acetyl-β-boswellic acid (AβBA), α-boswellic acid (αBA), and acetyl-α-boswellic acid
(AαBA)] was evaluated in the plasma and in a series of tissues (brain, muscle, eye, liver and
kidney), providing the first data on tissue distribution of BAs. Weight equivalent and equimolar
oral administration of Casperome™ provided significantly higher plasma levels (up to 7-fold for
KBA, and 3-fold for βBA quantified as area under the plasma concentration time curve, AUClast)
compared to the non-formulated extract. This was accompanied by remarkably higher tissue
levels. Of particular relevance was the marked increase in brain concentration of KBA and AKBA
(35-fold) as well as βBA (3-fold) following Casperome™ administration. Notably, up to 17 times
higher BA levels were observed in poorly vascularized organs such as the eye. The increased
systemic availability of BAs and the improved tissue distribution, qualify Casperome™ for further
clinical development to fully exploit the clinical potential of BE.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.Keywords:
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Bioavailability is a major hurdle in the translation of the
preclinical potential of many botanical extracts into therapeutic
effects, especially for those whose active ingredients show poorGerman Pharmacists,
Tel.: +49 61 96 937
del-Tawab).
Y-NC-ND license.water solubility and strong tendency to self-aggregate. This is
the case for many polyphenolics and triterpenoid acids.
Phospholipid-based delivery systems have been developed to
improve the oral availability of these compounds and the
extracts that contain them. Among different strategies, a
Phytosome® delivery form has emerged as a promising
“dietary” candidate [1,2]. Compared to liposomes, Phytosome®
is characterized by a high bioactive/lipid ratio [1] with an
overall stoichiometry in the range of 1:1–1:3 between the
active and the phospholipid formulation aid [3]. To date, the
90 J. Hüsch et al. / Fitoterapia 84 (2013) 89–98mechanism by which Phytosome® improves the absorption of
plant phenolics and terpenoids is not known. Presumably, two
processes are involved, namely improving their dispersion in
the intestinal fluids, and “chaperoning” them into the
enterocytes by lecithin [1,4]. The Phytosome® technology has
been successfully applied to herbal extracts (ginkgo, milk
thistle, green tea) as well as phytochemicals (curcumin,
silybin), with remarkable results both in animals as well as in
human pharmacokinetic studies [1,4–6].
Over the past two decades, extracts of the gum resin of
Boswellia serrata, a traditional ayurvedic medicine, have
become popular in Western countries. In vitro assays, animal
studies and pilot clinical trials have established a potential
for B. serrata gum resin extracts to alleviate a variety of
inflammatory conditions that include inflammatory bowel
disease, rheumatoid arthritis, osteoarthritis and asthma [7].
Furthermore, in 2002 the European Medicines Agency (EMA)
granted B. serrata gum resin extract the ‘orphan drug’ status
for the treatment of peritumoral brain edema [8]. The
mechanism(s) underlying the anti-inflammatory action of B.
serrata is (are) still under research. Early studies suggested that
two quantitatively minor boswellic acids (BAs) [11-keto-β-
boswellic acid (KBA) and acetyl-11-keto-β-boswellic acid
(AKBA)] could interfere with the production of leukotrienes
by inhibition of 5-lipoxygenase (5-LO). However, more recent
research has shown that other BAs, especially β-boswellic acid
(βBA), could also play an important role, targeting the
microsomal prostaglandin (PG) E2 synthase-1 (mPGES-1) as
well as cathepsin G (CatG) [7–10]. Thus intraperitoneal and
oral administration of a low dose of βBA (1 mg/kg) suppressed
pleurisy in the carrageenan-induced rat pleurisy model in vivo
which was accompanied by reduced levels of PGE2. Remark-
ably, AKBA caused no significant effects in this assay [9].
Pharmacokinetic studies have evidenced that the systemic
absorption of BAs, especially KBA and AKBA, was very low both
in animals and in humans [7,8], rationalizing efforts to
overcome their low oral bioavailability. In this context, the
excellent improvement of absorption recently reported for
Meriva® [11,12], a lecithin formulation of curcumin, and the
beneficial effects of a fatty meal on the bioavailability of BAs
[8,13] have prompted us to compare the bioavailability of BAs
in a soy lecithin formulation of a B. serrata extract (BE), and its
corresponding unformulated extract. The concentration of the
six major BAs (KBA, AKBA, βBA, acetyl-β-boswellic acid
(AβBA), α-boswellic acid (αBA), and acetyl-α-boswellic acid
(AαBA)) (Fig. 1) was evaluated in plasma and in a series of
tissues (brain, muscle, eye, liver and kidney), providing novel
data on the tissue distribution of BAs.
2. Material and methods
2.1. Standards and reagents
Boswellic acids (KBA, AKBA, αBA, βBA, AαBA and AβBA)
with purity>99% were obtained from Phytoplan GmbH,
Heidelberg, Germany. B. serrata extract (Batch N.: 11239, Code
N.: 36BW60090) (BE) and Casperome™ (Batch N.: 11411, Code
N.: 36BWP0090) applied in the rat study were kindly donated
by Indena S.A. (Tours, France). Casperome™ is a formulation
of a B. serrata extract (BE) and soy lecithin in a 1:1 ratio,
with about half part of microcrystalline cellulose being alsoadded to improve the physical state and to standardize
the product to a content of total triterpenoid acids by
HPLC of at least 25%. For the production of Casperome™
and BE the same lot of gum resin has been used. Blank
human plasma was obtained from Deutsches Rotes Kreuz-
Blutspendedienst, Mannheim, Germany. The reagents used
were tetrahydrofurane, n-hexane, dimethylsulfoxide (p.a. or
gradient grade, Roth, Karlsruhe, Germany), 2-propanol,
methanol (LC–MS, Roth, Karlsruhe, Germany), ethyl acetate
(LC–MS, Fluka, Sigma-Aldrich, Steinheim, Germany), dis-
tilled water, potassium dihydrogen phosphate, EXtrelut®
(Merck, Darmstadt, Germany), Tris (Roth, Karsruhe, Germany)
and ammonium formate (p.a., VWR, Leuven, Belgium).2.2. Animal study
Experiments were carried out according to the guidelines
of the German Protection of Animal Act (Deutsches
Tierschutzgesetz, BGBI 1998, Part I, No. 30, S. 1105 ff.).
Female albino Wistar rats weighing around 250 g were
fasted from the afternoon over night before they were
administered non-formulated BE (240 mg BSE/kg) or one of
two dose levels of Casperome™ (n=6 each) on the next
morning. The first dose level of Casperome™ equals in weight
to the administered extract and contains about 1/3 of the BAs
found in the non-formulated BE. The second Casperome™ dose
level corresponds to the molar content of the six boswellic
acids (BAs) in the non-formulated BE and equals roughly 2.5
times the weight of non-formulated BE. For that purpose
900.27 mg of BE was weighed in Falcon tubes, filled up to
15 mLwithwaterwhile shaking vigorously before 1 mL of that
suspension was administered orally to rats by gavage via a
pharyngeal tube. This corresponds to a dose of 240.07 mg/kg
BE. Based on the total content of 36.23% for the six BAs (KBA,
AKBA, βBA, AβBA, αBA, AαBA) determined in the BE, a total of
86.97 mg/kg of the six BAs were actually administered to rats
upon application of BE. In the case of Casperome™, containing
14.17% of the six BAs, 901.18 mg (equivalent net weight of BE)
and 2335.79 mg (equivalent molar ratio of BE), respectively,
were weighed into a test tube and rehydrated with 15 mL
water while shaking vigorously. Afterwards 1 mL of the
respective solution, corresponding to 34.06 mg/kg (equivalent
weight dosage to BE) and 88.28 mg/kg (equivalent molar
dosage to BE) of the six BAs was administered orally to rats.
Blood samples for plasma analysis were collected from the
retrobulbar venous plexus of the anesthetized animals after
defined time points (0.5, 1, 2, 3, 4, 6 and 8 h) in lithium-heparin
tubes, centrifuged and stored at−80 °C. After 3 h and 8 h, the
rats were dissected, and the brain was isolated, freed from
meninges and visible vasculatures, weighted and washed with
a Tris–HCl buffer solution (5 mM adjusted to pH 7.4). At these
time points also the eyes, muscle, kidney and liver were
isolated. In the case of the 3 h organ removal no plasma
samples were taken. Afterwards the brain and the other organs
were homogenized in Tris–HCl buffer (1 mL buffer/100 mg of
the respective organ) and stored at −20 °C until analysis. In
order to obtain better quantifiable results, the eyes of every two
rats have been pooled.
In summary, 36 animals were used in total, 18 rats (six per
group) for the generation of plasma and tissue data after 8 h
Fig. 1. Structures of boswellic acids.
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after 3 h.2.3. Sample preparation
Plasma and organ samples were thawed slowly at ambi-
ent temperature. For most of the plasma samples, only a
small amount of 100 μL was available, but the sample
preparation for the LC–MS/MS method used to determine
BAs in plasma was validated with 1 mL plasma. Thus, 900 μL
of blank plasma was added to 100 μL of the plasma samples
in order to obtain a total volume of 1 mL. In the case of
lower plasma volumes (e.g. 70 μL), the missing plasma was
filled up to volume with blank plasma (e.g. 930 μL) and the
calculated values were corrected for the actual sample. In
the case of the organ samples 1 mL of the homogenized
solution was used.
Then the samples were spiked with 25 μL of an internal
standard solution (containing 1 μg fluoxymesterone in
methanol) and 50 μL of pure methanol was added (to
correct for the volume spiked to blank plasma for the
preparation of the calibration samples). Afterwards the
samples were vortexed briefly prior to loading onto glass
cartridges filled with 0.8 g EXtrelut® NT. For matrix based
liquid–liquid extraction, the samples were eluted with 8 mL
of an extraction mixture consisting of tetrahydrofurane:
n-hexane:ethyl acetate:2-propanol (320:320:320:30; v/v/v/
v) after 15 min. The solution was then evaporated to dryness
(nitrogen stream, 40 °C) and reconstituted in 100 μL mobile
phase A. For complete dissolution the samples were
vortexed and treated in the ultrasonic bath for few minutes.
The insoluble residue was separated by centrifugation
(2 min; 10 °C, 4000 rpm). The supernatant was used for
LC/MS-analysis.
Calibration solutions were prepared by diluting the BA
stock solutions in methanol to the desired concentration. For
calibration, 1 mL of blank plasma, brain, muscle, eyes, liver and
kidney, respectively, were spiked with 50 μL of a calibration
solution to yield BA concentrations ranging between 5 and
10,000 ng/mL and 25 μL of the internal standard solution,
containing 1 μg fluoxymesterone. All calibration curves
resulted in linear correlation coefficients >0.98 thus fulfilling
the requirements of bioanalytical method validation.2.4. Sample analysis by LC/MS
The BA content in all samples was determined according to
a sensitive previously developed LC–MS/MS method [14]. In
brief, liquid chromatography was performed on an Agilent
1200 series equipped with a gradient pump with vacuum
degasser, an autosampler and a column oven. A Hypersil BDS
RP C18 column (100×4 mm; 3 μm; Thermo scientific), and an
upstream Gemini security guard cartridge (Phenomenex,
Germany) 4×3 mm were used for chromatography. Separa-
tion was achieved using a gradient program starting with 90%
mobile phase A (methanol:water 90:10, 400 mg/L ammonium
formate) and 10% mobile phase B (methanol:water 80:20,
400 mg/L ammonium formate) changing to 100%mobile phase
A within 20 min. This was kept constant for 14 min before
returning to the initial conditions within 1 min. The total run
timewas 35 min at a flow rate of 0.4 mL/min. The columnoven
was set to 35 °C and the autosampler was kept at room
temperature.
MS analysis was performed in the negative single ion mode
(SIM) on an Agilent Triple Quadrupole LC/MS 6410 series
(Agilent Technologies, Waldbronn, Germany) equipped with
anElectro Spray Ionization (ESI) source. Dwell timewas chosen
to be 200 ms. The Mass Hunter software was used for data
acquisition and processing.
Quantification of plasma and different organ samples was
carried out with the internal standard method using peak area
ratios.
2.5. Analysis of BE and Casperome™
The LC/MS method described above was used for the
determination of the content of the six BAs in BSE and
Casperome™ after diluting the respective samples to fit the
BA calibration range of 5–10,000 ng/mL.
2.6. Statistical analysis
All plasma data for the individual BAs were expressed
as mean of six rats±S.D. For statistical analysis the phar-
macokinetic parameters (AUC and Cmax) derived from the
plasma concentrations of the individual BAs have been
log-transformed and analyzed by one way ANOVA (p≤0.1).
The analysis was performed by the GLM procedure of SAS
Table 1
Doses of the individual boswellic acids administered orally in the form of
non-formulated BE extract and Casperome™ at equivalent weight and
equimolar dosages.
Non-formulated BE
(reference)
Casperome™
(equiweight
dosage)
Casperome™
(equimolar
dosage)
KBA 9.52 3.73 9.66
AKBA 7.65 3.00 7.77
αBA 13.44 5.26 13.64
βBA 28.13 11.02 28.56
AαBA 6.71 2.63 6.81
AβBA 21.58 8.45 21.91
Total [mg/kg] 86.97 34.06 88.28
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Bonferroni's adjustment for three comparisons, to calculate
the difference between LSMeans and its 90% confidence
interval. The ratio between samples was found by calculating
the anti-log of the difference between LSMeans.
When applicable, ANOVA was also performed on the
untransformed data of the other pharmacokinetic parame-
ters (Tmax, T1/2, Ke). If the F test of ANOVA was significant at
the 10% level (p≤0.10) at least, the multiple comparisons
were performed with Bonferroni's adjustment. Samples with
three replications at least have been analyzed. If the data of
only two samples were available the unpaired t test was
used.
The tissue data for the individual BAs are described by the
median, minimum and maximum concentrations. They have
not been subjected to ANOVA analysis, because of the high
interindividual variability and missing normal distribution.0
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Fig. 2. Mean plasma profiles of 11-keto-β-boswellic acid (KBA), acetyl-11-keto-β
administration of 240 mg/kg non-formulated Boswellia serrata extract [BE (nf)] and
means of six rats. For clarity purposes no error bars are shown. The mean plasma co
are listed in Table 2.3. Results
3.1. BA content in BE and Casperome™
BE contained 3.97% KBA, 3.19% AKBA, 11.72% βBA, 8.99%
AβBA, 5.60% αBA and 2.80% AαBA which added up to a total
BA content of 36.23%.
In comparison, Casperome™ contained 1.49% KBA, 1.25%
AKBA, 4.66% βBA, 3.50% AβBA, 2.24% αBA and 1.03% AαBA.
The sum of these BAs was 14.17%.
Two different dose levels of Casperome™were evaluated in
comparison to non-formulated BE. This allowed, in the first
case, to compare the absorption of the same weight of
formulated extract (Casperome™) versus the reference extract.
This comparison was sub-stoichiometric – Casperome™
contains only approximately 33% BE – involving a formulated
amount of a BE extract and a three-fold molar excess of its
corresponding non-formulated version. In the second case,
absorption of an identical molar dose of BAs was compared
between a lecithinized matrix (Casperome™) and the corre-
sponding non-formulated form. The doses of the individual BAs
administered to rats in the form of non-formulated BE and
Casperome™ at equivalent weight and molar doses are
summarized in Table 1. The concentration of the six major
BAs (KBA, AKBA,αBA, βBA, AαBA, and AβBA) was evaluated in
plasma as well as in highly (kidney, liver, brain) and poorly
perfused organs (muscle, eye).
3.2. Plasma concentration of BAs in rats
The dose of 240 mg/kg BE was chosen to enable
comparability with previous rat studies [15,16]. The mean
plasma concentration–time profiles of the pharmacologically
most relevant BAs are presented in Fig. 2. In addition the240 360 480
Csp (em) βBA
Csp (ew) βBA
BE (nf) βBA
Csp (em) AKBA
Csp (ew) AKBA
BE (nf) AKBA
Csp (em) KBA
Csp (ew) KBA
BE (nf) KBA
-boswellic acid (AKBA) and β-boswellic acid (βBA) in rats after the ora
Casperome™ (Csp) at equiweight (ew) and equimolar (em) doses. Values are
ncentrations±SD for the individual boswellic acids at every sampling poinl
t
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ters of the individual BAs are listed in Tables 2 and 3. The
ratios of the geometric means of the AUC and Cmax of both
Casperome™ dosages to the non-formulated extract and the
corresponding 90% confidence intervals are summarized in
Table 3 and visualized in Fig. 3a and b. As can be seen in
Table 3, the administration of Casperome™ at equivalent
weight dosage resulted in comparable or two times higher
Cmax and AUClast values, although only about 1/3 of the BA
content present in the BE extract was administered with
Casperome™ at this dosage. The difference was statistically
significant in the case of the AUClast and Cmax of βBA and in
the case of AUClast of KBA. For AβBA a statistically significant
decrease in the Cmax was observed.
The administration of Casperome™ at equimolar dosage
resulted in two- to three-fold higher plasma levels and two- to
six-fold increases in the AUClast for AKBA, αBA, KBA, and βBA.
Similar to the equiweight dosage, statistically significant
differences were observed for the AUClast and Cmax values of
KBA and βBA. AβBA and AαBA revealed comparable or slightly
decreased AUClast and Cmax values compared to the non-
formulated BE extract. Comparing both Casperome™ dosages
with each other, statistically significant higher AUC and Cmax
values were found for KBA and AKBA in the equimolar dosage.
The formulation of BE into Phytosome® form had generally noTable 2
Overview on the mean plasma levels [ng/mL] of 6 rats obtained for the individual BA
extract and Casperome™ at equivalent weight and equimolar dosages.
Sample Time [min] 0 30
KBA BE (not formulated) Mean 0 73.68
SD 0 87.14
Casperome™ (equiweight dosage) Mean 0 246.37
SD 0 96.28
Casperome™ (equimolar dosage) Mean 0 502.59
SD 0 358.41
AKBA BE (not formulated) Mean 0 90.13
SD 0 35.66
Casperome™ (equiweight dosage) Mean 0 147.17
SD 0 46.34
Casperome™ (equimolar dosage) Mean 0 255.06
SD 0 259.57
βBA BE (not formulated) Mean 0 102.54
SD 0 66.92
Casperome™ (equiweight dosage) Mean 0 293.14
SD 0 94.02
Casperome™ (equimolar dosage) Mean 0 341.20
SD 0 173.81
αBA BE (not formulated) Mean 0 79.49
SD 0 19.86
Casperome™ (equiweight dosage) Mean 0 113.60
SD 0 24.79
Casperome™ (equimolar dosage) Mean 0 111.44
SD 0 61.41
AαBA BE (not formulated) Mean 0 13.16
SD 0 20.05
Casperome™ (equiweight dosage) Mean 0 48.65
SD 0 23.57
Casperome™ (equimolar dosage) Mean 0 44.82
SD 0 28.15
AβBA BE (not formulated) Mean 0 84.91
SD 0 113.12
Casperome™ (equiweight dosage) Mean 0 104.19
SD 0 53.72
Casperome™ (equimolar dosage) Mean 0 101.94
SD 0 71.91effect on Tmax, nor on the half life (T1/2) nor on the elimination
of BAs (T1/2/Ke).
3.3. Tissue distribution of BAs in rats
The distribution of the pharmacologically most relevant
BAs in various organs is depicted in Fig. 4 and the data for the
distribution of all BAs are summarized in Table 4.
The highest uptake of all BAswas observed in the kidney and
in the liver. Upon the oral administration of Casperome™
equimolar dosage the level of the polar BAs, KBA and AKBA, in
the kidney and liver increased dramatically up to 24 times after
8 h, whereas most of the other BAs revealed 2–7 times higher
levels.
The brain levels of BAs differed according to the adminis-
tered formulation and the individual BAs. No KBA, and in the
case of AKBA only negligible amounts were detected in the
brain 3 and 8 h following the oral administration of the
reference extract. The availability of these two BAs was
markedly increased (up to 35 times in the case of AKBA),
when administered as Casperome™. Maximum brain tissue
concentrations were reached at 8 h and 3 h for the equimolar
and equivalent weight doses, respectively. In the case of αBA
and βBA, which represent non-acetylated BAs without a keto
group, up to 3 times higher brain levels compared to the extracts over a period of 8 h following the oral administration of non-formulated BE
60 120 180 240 360 480
51.03 45.09 164.39 66.53 15.45 90.42
85.48 50.15 197.40 136.90 13.55 183.44
229.64 196.83 165.86 158.17 112.70 74.09
129.13 68.20 87.37 78.95 44.24 39.99
523.95 537.56 506.33 424.15 371.69 334.71
194.70 292.33 233.98 206.89 46.52 140.70
133.21 189.78 242.31 253.00 183.57 157.39
128.41 98.15 95.66 53.90 25.33 27.48
195.27 172.43 156.30 120.60 68.45 21.72
125.45 39.65 77.88 82.41 36.81 28.63
362.12 458.93 470.18 426.26 319.93 174.84
251.95 385.29 307.98 297.16 104.98 112.14
368.42 488.61 715.05 800.09 682.18 619.02
401.60 212.86 197.83 243.57 146.90 254.07
588.57 972.43 1466.11 1321.64 1175.72 712.86
277.90 440.73 563.27 408.54 394.43 138.00
975.01 1315.75 2074.62 2199.22 2404.95 1755.34
522.15 374.56 2173.97 1150.45 660.83 864.11
151.90 222.40 393.76 378.86 340.97 332.52
137.20 82.78 238.81 72.50 61.08 105.79
197.08 314.44 487.47 469.12 435.86 307.22
70.07 86.51 218.43 136.73 127.57 110.26
255.39 574.40 652.57 750.20 927.27 674.39
148.61 541.71 491.21 535.36 521.02 190.17
88.35 141.07 267.12 428.07 442.58 407.14
105.40 67.10 96.34 139.21 139.57 126.65
104.64 202.63 336.62 351.33 351.56 293.39
42.22 68.10 147.81 90.59 98.07 84.18
119.51 320.08 404.47 474.56 799.66 593.46
83.30 245.87 255.10 294.23 296.33 127.46
399.63 634.11 1163.45 1730.15 2135.31 1590.11
376.41 309.33 386.46 512.03 1271.23 479.13
259.93 481.59 804.59 837.18 809.60 653.24
100.50 178.32 349.56 239.96 275.95 184.31
322.77 886.75 1119.97 1351.13 2240.78 1538.85
301.67 722.15 794.08 1049.83 1105.19 273.59
Table 3
Overview on the pharmacokinetic parameters of the individual BAs following the oral administration of non-formulated BE and Casperome™ at equivalent
weight and equimolar dosages.
Parameters BE
(not formulated)
Casperome™
(equiweight dosage)
Casperome™
(equimolar dosage)
Mean±SD Mean±SD Ratioa (90% CI)b Mean±SD Ratio (90% CI)
KBA
AUClast [ng/nL⁎h]c 505.71±308.22 1194.8±301.03 2.77 (1.41–5.43)*1 3190.8±1181.8 7.11 (3.62–13.95)*2
Cmax [ng/mL]d 288.54±162.93 275.81±93.21 1.06 (0.55–2.06) 746.69±293.31 2.83 (1.46–5.47)*3
Tmax [h]e 2.83±2.91 1.67±1.47 3.17±3.11
T1/2 [h]f 0.74±n.c.h 4.80±4.12 3.29±2.21
Ke [h−1]g 0.94±n.c.h 0.25±0.21 0.32±0.25
AKBA
AUClast [ng/nL⁎h]c 1481.09±266.71 888.30±276.22 0.58 (0.32–1.06) 2619.8±1425.1 1.53 (0.83–2.79)
Cmax [ng/mL]d 311.98±64.70 242.69±91.97 0.75 (0.41–1.35) 621.08±387.39 1.72 (0.95–3.11)
Tmax [h]e 3.17±1.17 1.58±1.11 4.17±2.40
T1/2 [h]f 6.73±5.25 1.18±0.87 4.19±5.17
Ke [h−1]g 0.14±0.07 0.80±0.40 0.66 (0.23–1.08)*4 0.36±0.26
βBA
AUClast [ng/nL⁎h]c 4714.8±664.49 8073.3±1862.8 1.69 (1.01–2.83)*5 12120.8±5427.6 2.29 (1.37–3.84)*7
Cmax [ng/mL]d 994.22±131.90 1692.5±383.85 1.68 (1.05–2.71)*6 3044.5±1877.9 2.69 (1.67–4.33)*8
Tmax [h]e 4.50±2.35 3.50±1.38 4.33±2.34
T1/2 [h]f 10.12±8.29 3.95±0.97 9.06±11.03
Ke [h−1] 0.12±0.08 0.18±0.04 0.20±0.16
αBA
AUClast [ng/nL⁎h]c 2352.6±355.06 2889.1±592.23 1.22 (0.66–2.25) 4644.8±2785.8 1.64 (0.89–3.03)
Cmax [ng/mL]d 511.21±172.05 572.02±198.28 1.11 (0.62–1.98) 988.09±606.76 1.72 (0.96–3.07)
Tmax [h]e 5.50±2.17 4.17±1.47 4.50±1.76
T1/2 [h]f 5.49±0.79 8.55±8.85 6.64±3.66
Ke [h−1]g 0.13±0.02 0.14±0.08 0.13±0.08
AαBA
AUClast [ng/nL⁎h]c 2297.9±530.47 2165.6±453.85 0.95 (0.47–1.91) 3341.6±1764.2 1.21 (0.60–2.43)
Cmax [ng/mL]d 536.88±75.41 435.41±114.49 0.8 (0.46–1.37) 727.34±368.95 1.19 (0.69–2.04)
Tmax [h]e 6.00±1.79 4.67±1.51 5.50±1.76
T1/2 [h]f 5.38±3.23 30.0±35.32 3.49±n.c.h
Ke [h−1]g 0.17±0.11 0.07±0.05 0.20±n.c.h
AβBA
AUClast [ng/nL⁎h]c 10595.7±2208.5 5061.44±1136.8 0.48 (0.22–1.03) 9265.9±5547.2 0.69 (0.32–1.49)
Cmax [ng/mL]d 2511.13±1050.7 1039.33±271.45 0.43 (0.22–0.83)*9 2080.3±1255.2 0.73 (0.37–1.42)
Tmax [h]e 6.33±1.51 4.67±1.51 5.00±1.55
T1/2 [h]f 6.05±0.37 16.58±16.59 34.47±44.50
Ke [h−1]g 0.12±0.01 0.08±0.05 0.12±0.16
*Indication for statistically significant differences: *1p=0.0090; *2pb0.0001; *3p=0.0065; *4p=0.0090 (difference) *5p=0.0919; *6p=0.0643; *7p=0.0056;
*8p=0.0006; *9p=0.0275.
a Ratio: geometric mean ratio of Casperome™ (equiweight and equimolar dosage) to non-formulated BE.
b CI: 90% confidence interval.
c AUClast: area up to the last validated measurable plasma concentration under the plasma concentration versus time curve.
d Cmax: mean maximal plasma concentration.
e Tmax: mean time required to Cmax.
f T1/2: the mean time taken for the plasma concentration to fall to half of its original value.
g Ke: mean overall elimination rate constant describing removal of the compound by all elimination processes including excretion and metabolism.
h n.c.: not calculated, because of insufficient data in the elimination phase.
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at equivalent weight dosage. For AαBA and AβBA, both
acetylated BAs without a keto group, comparable maximum
levels were achieved 3 h following the oral administration of
both Casperome™ doses.
In the muscle, equimolar Casperome™ yielded the highest
KBA and AKBA concentrations at 8 h after the oral dose (up to
15 times higher levels compared to the extract). Equiweight
Casperome™ produced the highest AαBA and AβBA at 3 h
after oral dosing (up to 15 times higher levels compared to
the extract). Both Casperome™ dose forms yielded the
highest αBA and βBA concentrations at 8 h after oral dosing,
being nearly 3 times higher than the corresponding concen-
trations of the extract.With the exception of αBA, AαBA and AβBA, the highest
BA concentrations in the eye were obtained with Casperome™
at equimolar dose at 8 h after oral dosing. In spite of the
low perfusion of the eye, between 1.8-times (for βBA) and
17-times (for KBA) higher BA concentrations compared to
the extract were observed.
4. Discussion
The oral absorption of BAs, especially of AKBA and KBA, is
reportedly poor in both rats and humans. Thus, a pharmaco-
kinetic study with one healthy volunteer taking three times
786 mg of a Boswellia extract over a period of 10 days led to
steady state levels of 0.1 μmol/L for AKBA and of 0.34 μmol/L
KBA: Csp (em) vs. BE (nf)
KBA: Csp (ew) vs. BE (nf)
AKBA: Csp (em) vs. BE (nf)
AKBA: Csp (ew) vs. BE (nf)
αBA: Csp (em) vs. BE (nf)
αBA: Csp (ew) vs. BE (nf)
αBA: Csp (em) vs. Csp (ew) 
βBA: Csp (em) vs. BE (nf)
βBA: Csp (ew) vs. BE (nf)
βBA: Csp (em) vs. Csp (ew) 
AαBA: Csp (em) vs. BE (nf)
AαBA: Csp (em) vs. Csp (ew) 
AαBA: Csp (ew) vs. BE (nf)
AβBA: Csp (ew) vs. BE (nf)
AβBA: Csp (em) vs. Csp (ew) 
AβBA: Csp (em) vs. BE (nf)
KBA: Csp (em) vs. Csp (ew) 
AKBA: Csp (em) vs. Csp (ew) 
-2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
AUC Ratio and its 90% CI
KBA: Csp (em) vs. BE (nf)
KBA: Csp (ew) vs. BE (nf)
AKBA: Csp (em) vs. BE (nf)
AKBA: Csp (ew) vs. BE (nf)
αBA: Csp (em) vs. BE (nf)
αBA: Csp (ew) vs. BE (nf)
αBA: Csp (em) vs. Csp (ew) 
βBA: Csp (em) vs. BE (nf)
βBA: Csp (ew) vs. BE (nf)
βBA: Csp (em) vs. Csp (ew) 
AαBA: Csp (em) vs. BE (nf)
AαBA: Csp (em) vs. Csp (ew) 
AαBA: Csp (ew) vs. BE (nf)
AβBA: Csp (ew) vs. BE (nf)
AβBA: Csp (em) vs. Csp (ew)
AβBA: Csp (em) vs. BE (nf)
KBA: Csp (em) vs. Csp (ew) 
AKBA: Csp (em) vs. Csp (ew) 
-2 -1 0 1 2 3 4 5 6
Cmax Ratio and its 90% CI
b
a
Fig. 3. Results of the statistical analysis of the AUC (a) and Cmax (b) values for the individual boswellic acids (BAs). The figure shows the 90% confidence intervals
(CI) of the geometric mean ratios of the equimolar Casperome™ dosage [CSP (em)] compared to the non-formulated extract [BE (nf)], of the equivalent weight
Casperome™ dosage [CSP (ew)] compared to BE (nf), and of CSP (em) compared to CSP (ew) for the individual BAs, respectively. Confidence intervals>1 indicate
significant differences between the respective administrations.
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Eye Brain Muscle Kidney Liver Eye Brain Muscle Kidney Liver Eye Brain Muscle Kidney Liver
BE (nf) 2.5 0 34.1 92.3 0 32.7 49.2 59.2 440.9 322.6 394.5 338 717.5 4308.8 1240.6
Csp (ew) 2 0 214.8 59.6 1024.8 99 65.2 492.4 170.7 1629.4 464.4 1088.4 1872.5 3594.2 3292.9
Csp (em) 41.9 175.4 474.4 1815 4798.8 315.8 609.8 911.4 4621.6 7761.5 725.1 407.5 1943.1 8525.2 8561.6
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Fig. 4. Median concentrations of 11-keto-β-boswellic acid (KBA), acetyl-11-keto-β-boswellic acid (AKBA) and β-boswellic acid (βBA) in the eye, brain, muscle,
liver and kidney of rats after 8 h of the oral administration of 240 mg/kg non-formulated Boswellia serrata extract [BE (nf)] and Casperome™ at equiweight and
equimolar doses [Csp (ew) and Csp (em)]. The range between the minimum and maximum concentrations of the three boswellic acids in the individual organs is
expressed by the line bars. The median, minimum and maximum concentrations for 11-keto-β-boswellic acid (KBA), acetyl-11-keto-β-boswellic acid (AKBA) and
β-boswellic acid (βBA) after 3 h and for all boswellic acids after 3 and 8 h from oral administration are listed in Table 4.
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healthy volunteers taking three times 800 mg B. serrata
extract over a period of 4 weeks led to steady state
concentrations of 0.04 μmol/L for AKBA and 0.3 μmol/L for
KBA [10]. Other pharmacokinetic studies applying single oral
B. serrata doses revealed even lower levels for AKBA, being
often not detectable [8,13,18]. Solely in one study on 12
human volunteers KBA reached maximum plasma levels of
2.7 μmol/L following the administration of 333 mg B. serrata
extract after meal [18]. Of all BAs, only βBA and AβBA
revealed acceptable plasma levels in the range of 6.35–
10.1 μmol/L for βBA and 2.4–4.9 μmol/L for AβBA, which may
be attributed to their higher contents in the extract [10,17].
The present pilot study clearly demonstrates – with a
proof-of-concept approach in animals – that the absorption
and tissue distribution of BAs can be markedly increased by
using a phospholipid-based delivery form (Casperome™) of
BE. This is a pivotal finding, especially in the light of the
stoichiometry bias of the equivalent weight comparison. The
molecular bases underlying the observed improved absorption
and tissue uptake are still not known. On the other hand,
consistent evidence that fatty meals substantially improve, to
different extents, the low absorption of BAs has been reported
[8,13]. This effect is presumably due to the capacity of biliary
acids to improve the solubility of BAs, facilitating their
dispersion in the intestinal fluids and their eventual absorption.
It is believed that phospholipids could play a similar role. In
fact, the pharmacologically most important BAs, i.e. KBA, AKBA
and βBA, have achieved markedly increased levels in plasma.Interestingly, while for KBA and βBA a statistical significant
increase, in comparison to the non formulated BE, in both
AUClast and Cmax was obtained, αBA, AKBA, AαBA and AβBA
resulted in comparable or almost two times higher levels in the
equimolar comparison but without reaching statistical signif-
icance. This may be attributable to the low power of the study
but also to the greater lipophilicity of AαBA and AβBA which
might be associated with a slower uptake and probably with a
stronger retention in the Phytosome® making differences
probably obvious at later time points than 8 h. It has to be
underlined that these higher plasma levels were accompanied
with a better distribution of all BAs in all tissues investigated.
This is evident for the concentration in the brain and muscle of
KBA, quantified at 0.4 and 1 μmol/g, AKBA at 1.2 and 1.8 μmol/g,
and βBA at 2.4 and 4.3 μmol/g, respectively. These tissue
concentrations, achieved for the first time following oral
administration of BE in a murine model, are within the range
of the IC50 values observed in vitro for the inhibition of 5-LO
(1.5 μM for AKBA), mPGES-1 (5 μM for βBA) and CatG (0.6 μM
for AKBA, 0.8 μM for βBA) [8]. Increased tissue concentrations
(up to 17-fold) were also observed in poorly vascularized
organs like the eye, as well as in excretory organs like the liver
and the kidney. These results are of particular clinical impor-
tance because it has been shown in a former study that orally
administered phospholipid complexed BAs exerted a three-fold
greater anti-inflammatory activity in carrageenan-induced rat
paw edema compared to non-formulated BAs [19].
Previous attempts to improve the absorption of BAs in
vivo by phospholipid formulation used an equivalent BE as
Table 4
Overview on the median tissue levels of 6 rats and the range between the minimum and maximum values obtained for the individual BAs after 3 h for KBA, AKBA and βBA and after 3 and 8 h for αBA, AαBA, and AβBA
following the administration of non-formulated BE extract [BE (nf)] and Casperome™ at equivalent weight [Csp (ew)] and equimolar [Csp (em)] dosages (n=6). The 8 h values for KBA, AKBA and βBA are shown in Fig. 4.
h KBA [ng/g] AKBA [ng/g] βBA [ng/g]
Eye Brain Muscle Kidney Liver h Eye Brain Muscle Kidney Liver h Eye Brain Muscle Kidney Liver
BE (nf) 5.67 0.00 47.05 226.7 868.49 3 25.59 9.63 79.81 885.2 687.00 3 123.4 0.0 260.24 3208.8 1012.29
Min–max 3.81–
97.78
0.00–
44.93
25.61–
67.21
158.7–
494.0
105.98–
1740.52
19.62–
120.39
0.00–
45.01
24.21–
113.37
256.3–
1773.1
239.36–
1991.06
88.79–
790.76
0.00–
98.20
143.40–
331.01
1341.6–
8199.3
777.22–
1900.03
Csp (ew) 12.95 62.10 51.09 683.6 1407.78 3 85.03 314.91 84.28 1716.2 2166.14 3 699.54 886.64 1171.70 4922.4 3132.40
Min–max 0.00–
382.57
36.15–
458.56
17.64–
110.98
444.1–
852.6
598.03–
3171.14
30.01–
704.89
257.21–
462.88
16.88–
341.10
1118.3–
2019.3
503.64–
4673.15
623.45–
5264.20
545.38–
976.64
421.00–
3273.62
4345.1–
6879.9
1090.76–
5364.16
Csp (em) 19.39 121.23 131.11 474.0 131.23 3 119.4 343.79 210.64 1432.4 443.20 3 466.76 700.86 823.40 5626.9 2840.15
Min–max 1.18–
145.70
0.00–
586.11
67.90–
318.17
355.9–
1153.0
0.00–
2028.10
63.97–
311.82
22.47–
477.86
152.27–
674.23
333.5–
2631.8
337.34–
560.84
302.64–
2046.95
0.00–
1376.85
496.39–
1796.12
1942.0–
8045.3
946.56–
6120.26
3/8 h αBA [ng/g] AαBA [ng/g] AβBA [ng/g]
Eye Brain Muscle Kidney Liver h Eye Brain Muscle Kidney Liver h Eye Brain Muscle Kidney Liver
BE (nf) 41.82 9.63 105.67 1486.6 1188.48 3 8.04 7.34 6.72 151.24 252.56 3 24.65 0.00 35.02 494.46 743.65
162.09 283.76 213.99 1884.5 1188.22 8 32.48 59.47 63.99 536.73 489.15 8 113.24 101.52 179.02 1778.8 1450.58
Min–max 39.90–
297.97
0.00–
32.51
48.71–
130.25
616.0–
5738.3
451.83–
1866.05
3 6.99–
156.60
1.48–
18.10
2.54–
18.37
45.5–
233.5
116.87–
467.89
3 19.04–
513.63
0.00–
0.00
0.00–
51.24
165.6–
3596.4
379.07–
1353.87
111.00–
170.13
241.32–
380.62
127.09–
466.50
1427.2–
3036.6
728.91–
2661.54
8 23.12–
53.13
39.92–
93.14
4.75–
185.87
457.6–
863.8
350.04–
900.02
8 74.78–
169.82
35.55–
318.95
127.70–
541.28
1371.4–
2596.9
1161.39–
2920.29
Csp (ew) 323.80 381.86 366.33 3358.4 3999.32 3 76.18 120.34 103.82 340.83 613.86 3 239.72 402.96 394.37 1121.55 1748.36
166.08 496.85 641.92 2246.4 4666.33 8 17.16 54.94 96.60 581.56 1697.43 8 56.53 53.60 353.51 1675.28 4694.31
Min–max 252.23–
1262.35
363.39–
578.21
148.59–
783.52
2515.6–
3978.7
1085.44–
5326.06
3 51.63–
801.54
74.81–
252.30
68.98–
728.59
241.8–
548.7
189.79–
1027.21
3 146.63–
2453.15
185.66–
1057.25
186.29–
2540.04
798.7–
1566.9
461.73–
3310.44
130.29–
201.87
280.43–
1883.21
393.89–
844.36
1046.6–
4045.3
2798.76–
6410.02
8 13.22–
21.11
16.33–
161.29
59.86–
173.51
395.8–
888.4
857.61–
2240.24
8 38.60–
74.45
0.00–
507.33
177.01–
579.75
1523.9–
2735.5
2464.10–
5849.21
Csp (em) 149.11 354.37 214.42 3057.8 3121.23 3 3.04 161.83 54.44 342.19 836.25 3 99.53 421.76 189.33 1116.7 1711.31
232.1 323.84 604.47 5029.9 6962.93 8 2.62 35.99 96.03 581.46 1862.09 8 89.06 74.14 320.50 1849.55 5529.76
Min–max 104.85–
512.79
30.31–
724.36
188.12–
367.74
1107.5–
4404.5
1008.01–
8667.62
3 1.76–
23.45
23.63–
353.08
28.25–
86.27
92.4–
480.0
527.86–
2115.64
3 52.52–
755.93
33.93–
1269.12
94.55–
248.91
396.8–
1414.5
1273.56–
5076.54
220.20–
808.89
219.93–
850.08
224.40–
1197.10
2586.0–
6018.4
5032.17–
10,793.85
8 1.86–
39.21
10.96–
100.93
33.72–
238.63
277.7–
952.3
955.92–
4936.19
8 86.35–
1217.22
4.56–
317.72
111.36–
846.04
819.2–
2587.1
3763.94–
11314.05
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98 J. Hüsch et al. / Fitoterapia 84 (2013) 89–98the one used in this study, in a 1:1:1 (w/w/w) formulation of
BE:lecithin:pluronic f127 (co-surfactant) mixed at a 1:1 ratio
with microcrystalline cellulose [20]. When compared to
Casperome™ on equimolar basis, this formulation led to
roughly 1.5-fold higher mean plasma levels for KBA, AKBA
and βBA, as well as higher mean brain levels for βBA (roughly
10-fold). On the other hand, Casperome™, that only uses
dietary formulation ingredients, outperformed this formula-
tion in terms of mean brain levels of AKBA (3-fold) and KBA
(almost 30-fold).
The present investigation is a preliminary pilot study carried
out on a small number of rats for exploratory reasons only, to
support the higher absorption expected for phospholipid-based
delivery forms of B. serrata extracts. Nevertheless the results
clearly indicate that the absorption of BAs is substantially
improved by formulating BAs with lecithin as achieved in
Casperome™. Further mechanistic studies will be necessary to
understand how absorption and tissue capitation of BAs
associated to lecithin formulation improve. For that purpose a
larger number of rats would need to be included, in order to
compensate for the high interindividual variability observed in
this preliminary study. Larger number of rats is also advisable
because the present design based on the quantification of the
individual boswellic acids in the different tissues prevents a
crossover design, which is usually applied in comparative
formulation studies.
In summary, the results of the present study, which suggest
that the organ concentrations achieved match the required
range to elicit pharmacological action of BAs on inflammatory
targets, encourage the translation of these findings into the
human organism.
5. Conclusion
On accounts of its potent anti-inflammatory action, B. serrata
represents a potential remedy for the complementary treatment
of various inflammatory chronic diseases including the reduc-
tion of peritumoral edema. A major limitation is the very poor
oral bioavailability of its active constituents (boswellic acids)
which has so far hampered the clinical translation of the very
promising preclinical efficacy data on this ingredient. We have
shown that lecithin formulation significantly improves the
absorption of BAs and promotes their tissue penetration,
demonstrating for the first time the achievement of tissue
concentrations of these compounds in the range of their
anti-inflammatory activity. Taken together, these results pro-
vide a rationale for investigating the clinical potential of
Casperome™ in a variety of conditions where preclinical
evidence of action for BE has been reported.
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